The Spine Journal
Volume 11, Issue 12 , Pages 1093-1100, December 2011

Adverse events of conscious sedation in ambulatory spine procedures

  • Michael K. Schaufele, MD

      Affiliations

    • Emory Orthopaedics & Spine Center, Emory Healthcare, 59 Executive Park South, Atlanta, GA 30329, USA
    • Corresponding Author InformationCorresponding author. The Emory Spine Center, Emory University School of Medicine, 59 Executive Park South, Atlanta, GA 30329, USA. Tel.: (404) 778-7168; fax: (404) 778-7177.
  • ,
  • Daniel R. Marín, MD

      Affiliations

    • Comprehensive Spine Care Program, Department of Neurosurgery and Brain Repair, University of South Florida, 2 Tampa General Circle, Tampa, FL 33606, USA
  • ,
  • Jordan L. Tate, MD, MPH

      Affiliations

    • Department of Rehabilitation Medicine, 1441 Clifton Rd, Atlanta, GA 30322, USA
  • ,
  • Adam C. Simmons, MPH, CCRC

      Affiliations

    • Clinical Research Development and Operations, Children's Hospital Boston, 300 Longwood Ave, Boston, MA 02115, USA

Received 29 October 2010; received in revised form 20 May 2011; accepted 29 July 2011. published online 19 September 2011.

Abstract 

Background context

Interventional spine procedures are commonly performed in the ambulatory surgical setting, often using conscious sedation. The rate of adverse events with conscious sedation has not been previously assessed in the interventional spine procedure setting.

Purpose

The goal of this study was to determine the rate of adverse events when using conscious sedation in the ambulatory interventional spine setting.

Study design

A retrospective cohort chart review analysis was performed on all interventional spine procedures performed during one calendar year at a university-affiliated ambulatory surgery center by six nonanesthesia-trained spine interventionalists.

Patient sample

Of the 3,342 procedures performed that year, 2,494 charts (74.6%) were available for review.

Outcome measures

Adverse events were documented immediately after the procedure and at a maximum 3-day follow-up phone call.

Methods

The rate and type of adverse events were analyzed and compared between those who received conscious sedation with local anesthesia and those who received local anesthesia alone.

Results

Of the 2,494 cases reviewed, 1,228 spine procedures were performed with local anesthesia and conscious sedation, and 1,266 procedures were performed with local anesthesia alone. Of these cases, 66 immediate adverse events (5.12%) were documented in the conscious sedation group, and 61 immediate adverse events (4.82%) were documented in the local anesthesia alone group. At maximum 3-day follow-up, 670 patients of the conscious sedation group were available for contact, and 699 patients were available from the local anesthesia group. Thirty-two adverse events (4.77%) were noted in the conscious sedation group, and 28 adverse events (4.00%) were noted in the local anesthesia group. Comparison of these rates found no significant statistical difference. However, patients in the local anesthesia group had a significantly higher rate of postoperative hypertension. Adverse events reported both immediately and at follow-up were determined to be mild, with no serious adverse events reported.

Conclusion

The findings of this study suggest that mild to moderate conscious sedation in interventional spine procedures is associated with low rates of adverse events when established protocols are followed.

Keywords: Conscious sedation, Adverse event, Interventional spine procedure, Epidural

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 FDA device/drug status: Approved (lidocaine, bupivacaine, midazolam, and fentanyl).

 Author disclosures: MKS: Consulting: Medtronic (B); Scientific Advisory Board: Smith and Nephew (B); Fellowship Support: Medtronic (C). DRM: Nothing to disclose. JLT: Nothing to disclose. ACS: Nothing to disclose.

 The disclosure key can be found on the Table of Contents and at www.TheSpineJournalOnline.com.

PII: S1529-9430(11)00520-1

doi:10.1016/j.spinee.2011.07.028

The Spine Journal
Volume 11, Issue 12 , Pages 1093-1100, December 2011